Japan: Generics and Off-Patent Medicines Sandoz Completes Acquisition of Aspen’s Japanese Operations

Sandoz announced the successful acquisition of Aspen’s Japanese operations and assets. The transaction is to reinforce the company's strategic focus on Japan, the world’s third largest market for generics and off-patent medicines.

Holzkirchen/Germany – Sandoz announced that it has successfully completed the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen Pharmacare Holdings Limited. Sandoz has acquired all of the shares in Aspen Japan K.K. and associated assets held by AGI.

The acquisition enables the company to expand its presence in Japan’s marketplace, the third largest for generics and off-patent medicines worldwide. It also strengthens their presence in the hospital channel by complementing the portfolio and pipeline of hospital generic and biosimilar products in Japan with a dedicated sales, marketing and medical organization.

This article is protected by copyright. You want to use it for your own purpose? Contact us at support.vogel.de (ID: 46342723)